B-Y. Ryoo

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

R.S. Finn, Masatoshi Kudo, Philippe Merle et al. · Annals of Oncology · 2022 · 196 citations

Medicine, Oncology, Pharmacology +13

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer

Y-K. Kang, Hye Jin Kang, Dae Young Zang et al. · British Journal of Cancer · 2008 · 136 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

Dok Hyun Yoon, M.-H. Ryu, Y S Park et al. · British Journal of Cancer · 2012 · 87 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer

Y H Park, B-Y. Ryoo, S. R. Choi et al. · British Journal of Cancer · 2004 · 81 citations · Full text

Medicine, Oncology, Pharmacology +15

A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer

Y H Park, B-S Kim, B-Y. Ryoo et al. · British Journal of Cancer · 2006 · 70 citations · Full text

Medicine, Oncology, Pharmacology +17